Medical Device | June 30, 2022
NADMED brings first CE-marked NAD+ analysis kit to the market
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
We must try to make the health care system more accessible for people with disabilities
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
The Minister lauded and extended his gratitude to the scientists who developed the vaccine during pandemic.
First and only PARP inhibitor to improve invasive disease-free survival in patients
Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately $5 million in cash, plus contingent payments of up to $45 million.
The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
Subscribe To Our Newsletter & Stay Updated
